On February 6, 2019, Catabasis Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of an aggregate of 4,000,000 units at a public offering price of $5.00 per unit. Each unit is comprised of one share of common stock and 0.5 of a warrant to purchase one share of common stock for a total of 4,000,000 shares of common stock and warrants to purchase 2,000,000 shares of common stock. Oppenheimer & Co. Inc. is acting as sole underwriter for the offering.
The WilmerHale team representing Catabasis is led by Rosemary Reilly and includes Jeffries Oliver-Li, Jasmine Haddad and Victoria Hartmann.